Advanced Malignancies
84
12
15
42
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
18 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
12 terminated out of 84 trials
77.8%
-8.8% vs benchmark
6%
5 trials in Phase 3/4
43%
18 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 42 completed trials
Clinical Trials (84)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Clinical Study of BR105 Injection
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
A Study of BR111 in Patients With Advanced Malignancies
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies